This starting dose is usually between 1,000–1,250 mg/m, 1 which is generally administered ... narrow therapeutic windows. Capecitabine (Xeloda ™; Roche, Nutley, NJ) is an oral prodrug of ...
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.
Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS/NRAS/BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer Females with MBC and any previous lines of therapy ...
During the first cycle of capecitabine development, three concomitant drugs were found to affect 5-FU clearance. [5] Paracetamol and morphine increased 5-FU clearance by 26% and 41%, respectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback